Biomarkers of the tumour immune microenvironment and intrinsic characteristics of tumour cells, such as PD‐L1 expression, tumour‐infiltrating lymphocyte density (TIL), tumour mutational load and mismatch repair (MMR) defects, correlate with the efficacy of anti‐PD‐1/anti‐PD‐L1 therapy. This evidence concerns the gene CD274 and neoplasm.